Artelo Biosciences (ARTL) Convertible Debt (2025)
Artelo Biosciences' (ARTL) quarterly Convertible Debt came in at $609000.0 in Q4 2025, down 30.4% quarter-over-quarter from $875000.0 in Q3 2025.
Powered by 
Analysis
Artelo Biosciences (ARTL) Convertible Debt (2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Convertible Debt for 1 consecutive years, with $609000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $609000.0 in Q4 2025; TTM through Dec 2025 was $609000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $609000.0, changed N/A from the prior year.
- Convertible Debt was $609000.0 for Q4 2025 at Artelo Biosciences, down from $875000.0 in the prior quarter.
- Over five years, Convertible Debt peaked at $875000.0 in Q3 2025 and troughed at $609000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Artelo Biosciences | 120,353.04 | -479,646.96 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 609,000.00 |
| Sep 30, 2025 | 875,000.00 |
| Jun 30, 2025 | 791,000.00 |